By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during

By Ankit Mahadevia, former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC The right leaders in the right structure can power companies to great things. The general consensus is that all companies need a

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From the Trenches feature of LifeSciVC Well, this is a first…. while I have read and enjoyed the the LifeSci VC blog for years, being asked to contribute for

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Just in time for new years’ reflections and resolutions, this year’s JPM felt like a refreshing burst of enthusiasm for a sector that

Biotech feels like it’s got some wind in its sails here at the start of 2024, with positive sentiments from the JPM conference. Indeed, the public equity markets feeling somewhat buoyant for the first time in ages. With the close

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used by nature to

After the bursting of the pandemic biotech bubble, talk of industry consolidation was ubiquitous. The sector had pushed out too many IPOs during the go-go years, leading to too many public biotech companies, with sub-scale enterprises, and wasteful crowding in

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. @JebKeiper Earlier this year, Nimbus closed the sale of our allosteric TYK2 program, which was acquired by Takeda for $4 billion upfront. To

2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. Fortunately, despite all that, great science and medicine continues to

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC As we enter the final leg of 2023, navigating the investment market in biotech continues to be fraught with twists and turns. The

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I remember vividly my first vacation with the man who would be my husband.  In the days before Airbnb and on-line travel websites, he

By Ankit Mahadevia, Chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Nobody stays in a particular role forever. While change at the senior level can be disruptive, it doesn’t have to be. Teams and